Will P Steward
Overview
Explore the profile of Will P Steward including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
235
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Valle J, Wasan H, Lopes A, Backen A, Palmer D, Morris K, et al.
Lancet Oncol
. 2015 Jul;
16(8):967-78.
PMID: 26179201
Background: Cisplatin and gemcitabine is the standard first-line chemotherapy regimen for patients with advanced biliary tract cancer; expression of VEGF and its receptors is associated with adverse outcomes. We aimed...
2.
Haqq J, Howells L, Garcea G, Metcalfe M, Steward W, Dennison A
Eur J Cancer
. 2014 Aug;
50(15):2570-82.
PMID: 25091797
Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant disease with a very poor prognosis. To date patient outcomes have not improved principally due to the limited number of patients...
3.
Scott E, Garcea G, Doucas H, Steward W, Dennison A, Berry D
HPB (Oxford)
. 2009 Jul;
11(2):118-24.
PMID: 19590634
Background: The majority of patients with pancreatic cancer are non-resectable and jaundiced at presentation. Methods of palliation in such patients with locally advanced disease comprise endoscopic placement of a biliary...
4.
Garcea G, Doucas H, Steward W, Dennison A, Berry D
ANZ J Surg
. 2006 Aug;
76(9):830-42.
PMID: 16922908
Background: Pancreatic cancer remains one of the most lethal of all solid tumours of the gastrointestinal tract. It is characterized by late diagnosis, aggressive local invasion, early metastasis and resistance...
5.
Lee L, Sharma S, Morgan B, Allegrini P, Schnell C, Brueggen J, et al.
Cancer Chemother Pharmacol
. 2005 Sep;
57(6):761-71.
PMID: 16172907
PTK/ZK is a novel, oral angiogenesis inhibitor that specifically targets all 3 vascular endothelial growth factor (VEGF) receptor tyrosine kinases and is currently in phase III clinical trials. In early...
6.
Garcea G, Dennison A, Steward W, Berry D
ANZ J Surg
. 2003 Sep;
73(9):680-6.
PMID: 12956781
Background: There has been considerable interest in the use of chemical or dietary agents to suppress or inhibit the development of tumours in the early stages of carcinogenesis. This concept...
7.
Colquhoun A, Jones G, Moneef M, Bowman K, Kockelbergh R, Paul Symonds R, et al.
J Urol
. 2003 May;
169(6):1983-92.
PMID: 12771703
Purpose: Muscle invasive bladder cancer is a common urological malignancy with a relatively poor prognosis and 5-year survival rates ranging from 20% to 90%. We review methods of improving the...
8.
Ratan H, Steward W, Gescher A, Mellon J
Urol Oncol
. 2002 Dec;
7(6):223-7.
PMID: 12504842
The incidence of prostate cancer in Western countries continues to rise. Whilst opinion remains divided on the best treatment for localized disease, intervention for metastatic, hormone-independent cancer remains extremely limited....